| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
|
Eikelboom, John
|
|
2016
|
129 |
11S |
p. S33-S40
8 p.
|
article
|
| 2 |
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures
|
Levy, Jerrold H.
|
|
2016
|
129 |
11S |
p. S47-S53
7 p.
|
article
|
| 3 |
Evidence Supporting Idarucizumab for the Reversal of Dabigatran
|
Pollack Jr., Charles V.
|
|
2016
|
129 |
11S |
p. S73-S79
7 p.
|
article
|
| 4 |
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols
|
Huisman, Menno V.
|
|
2016
|
129 |
11S |
p. S89-S96
8 p.
|
article
|
| 5 |
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects
|
Reilly, Paul A.
|
|
2016
|
129 |
11S |
p. S64-S72
9 p.
|
article
|
| 6 |
Introduction to Direct Oral Anticoagulants and Rationale for Specific Reversal Agents
|
Pollack Jr., Charles V.
|
|
2016
|
129 |
11S |
p. S31-S32
2 p.
|
article
|
| 7 |
Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents
|
Milling Jr., Truman J.
|
|
2016
|
129 |
11S |
p. S80-S88
9 p.
|
article
|
| 8 |
Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
|
Milling Jr., Truman J.
|
|
2016
|
129 |
11S |
p. S54-S63
10 p.
|
article
|
| 9 |
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies
|
Villines, Todd C.
|
|
2016
|
129 |
11S |
p. S41-S46
6 p.
|
article
|
| 10 |
Table of Contents
|
|
|
2016
|
129 |
11S |
p. A3-A4
nvt p.
|
article
|
| 11 |
Title Page
|
|
|
2016
|
129 |
11S |
p. A1-
1 p.
|
article
|
Journal description